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Abstract We recently reported that A'.A'-dimethylsphingosine 
1-phosphate (DMS-l-P) can be formed from Ar,Ar-dimethyl-
sphingosine (DMS) in activated platelets |Y. Yatomi et al., 
Biochem. Biophys. Res. Commun. 231 (1997) 848-851]. In this 
study, we synthesized, for the first time, DMS-l-P and examined 
the functional effects of DMS-l-P and its related sphingolipids 
on platelets. Although exogenous DMS was inactive, its 
phosphorylated derivative, DMS-l-P, induced platelet intracel-
lular Ca2+ mobilization and shape change, but not aggregation or 
release reactions. Since sphingosine I-phosphate (Sph-l-P) is 
structurally related to DMS-l-P and activates platelets more 
strongly than DMS-l-P, a competitive binding experiment for 
[3H]Sph-l-P was performed using DMS-l-P. DMS-l-P reduced 
the binding of [ H]Sph-l-P to platelets almost as much as 
unlabeled Sph-l-P did. These results suggest that DMS-l-P 
activates platelets via an interaction with a platelet surface 
receptor for Sph-l-P. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The sphingolipids, whose fundamental backbone structure 
is sphingosine (Sph), have been shown to be signal-transduc-
ing lipids [1-5]. The distinguishing characteristic of the sphin-
golipids is their participation in the pro- or anti-proliferative 
pathways of cell regulation. Ceramide (Cer) [1-3] and Sph 
[6,7] are claimed to be important in the regulation of pro-
grammed cell death (apoptosis), while sphingosine 1-phos-
phate (Sph-l-P) induces mitogenesis and has been implicated 
as a second messenger in the cellular proliferation induced by 
platelet-derived growth factor and serum [3,5]. 
Anucleate blood platelets are considered to be a model 
system for working out stimulus-response coupling pathways, 
which have general implications for other cell types. Evidence 
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has accumulated on the involvement of glycerophospholipid 
metabolites in platelet signaling pathways [8]. However, less is 
known of the signaling pathways and the functional effects of 
sphingolipids in these non-proliferative, terminally differenti-
ated cells. We previously reported that Sph-l-P, which is the 
initial product of catabolism of Sph [3,5], induces platelet 
shape change and aggregation reactions by itself and syner-
gistically elicits aggregation in combination with weak platelet 
agonists such as epinephrine and ADP [9,10]. These functional 
responses, induced by Sph-l-P, were accompanied by intra-
cellular Ca2+ mobilization [9,10] and activation of the non-
receptor tyrosine kinase Syk [11]. These findings suggest that 
Sph derivatives can be signaling molecules not only in 
nucleated cells but also in anucleate platelets. Furthermore, 
we recently investigated the metabolism of various Sph deriv-
atives in human platelets and reported that A^TV-dimethyl-
sphingosine 1-phosphate (DMS-l-P) can be generated from 
Ar,ALdimethylsphingosine (DMS) upon agonist stimulation, 
the first report to describe the formation of DMS-l-P in a 
biological system [12]. Although the physiological significance 
of this phosphorylated and methylated Sph DMS-l-P is un-
known, it is important that the action of this novel sphingo-
lipid be elucidated considering that both Sph-l-P [3-5,10] and 
DMS [4,13,14] have important and distinct functions in the 
signal transduction pathways and that DMS-l-P could be an 
inhibitor of Sph-l-P lyase [15]. In this study, we describe a 
method for DMS-l-P preparation and show that exogenous 
DMS-l-P activates platelets, through its action on a postu-
lated Sph-l-P receptor. 
2. Materials and methods 
2.1. Materials 
Sph-l-P was prepared from sphingosylphosphorylcholine (SPC) 
with bacterial phospholipase D [16]. DMS [13] and 7V-acetylsphingo-
sine (C2-Cer) [17] were synthesized as described previously. Ceramide 
1-phosphate (Cer-l-P) was prepared by diacylglycerol kinase-cata-
lyzed phosphorylation of Cer. Lactosylceramide was prepared from 
dog erythrocytes [18]. [3-3H]Sph-l-P was prepared by ATP-dependent 
phosphorylation of [3-3H]Sph catalyzed by Sph kinase obtained from 
BALB/c 3T3 fibroblasts [19]. 
The following materials were obtained from the indicated suppliers: 
Sph, Cer (type III), and DL-^reo-dihydrosphingosine (Sigma, St. 
Louis, MO); fura2-AM (Molecular Probes, Eugene, OR); [3-3H]Sph 
(22.0 Ci/mmol) (Du Pont-New England Nuclear, Boston, MA). 
2.2. DMS-l-P preparation 
Attempts to prepare DMS-l-P from Sph-l-P by reductive methyl -
ation were not successful, presumably due to the insolubility of Sph-1 -
P under such reaction conditions. Therefore, we synthesized D-eryth-
re-DMS-1-P by a semi-enzymatic approach (Scheme 1), using SPC as 
a starting material. Since SPC purchased from Sigma was a mixture of 
the D-erythro- and L-threo forms [16,20], reductive methylation of SPC 
afforded dimethyl-SPC (DMSPC) as a mixture of both stereoisomers, 
which were readily separated by chromatography on silica gel. Treat-
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(a) 37% CHjO, NaCNBHj, NaOAc - HOAc; (b) Phospholipase D, 50 mM NH4OAc buffer (pll = 8) 
Scheme 1. 
ment of D-erythro-DMSPC with phospholipase D (Streptomyces chro-
mofuscus) gave D-erythro-DMS-1-P. The configuration of DMS-l-P 
was confirmed by NMR analysis (data not shown). Unlike Sph-l-P, 
D-erythro-DMS-1-P was quite water-soluble. 
2.3. Platelet preparation 
Washed platelets (3xl08/ml) were prepared as described [9], and 
supplemented with 1 mM CaCl2 unless stated otherwise. For the 
shape change studies, the platelets were left for at least 60 min at 
37°C after their final centrifugation, because this resulted in a greater 
response. All of the experiments using intact platelet suspensions were 
performed at 37°C. 
2.4. Platelet shape change and aggregation 
Platelet shape change and aggregation were determined turbidimet-
rically in a platelet ionized calcium aggregometer (PICA) (Chrono-
Log, Havertown, PA), while being stirred at 1000 rpm. The instru-
ment was calibrated with a platelet suspension for zero light trans-
mission and the buffer for 100% transmission. When aggregation was 
measured, human fibrinogen (500 ug/ml) was added to platelet sus-
pensions shortly before the addition of stimuli. 
The shape change was observed by adding 5 mM EDTA (instead of 
Ca2+) before stimulation to prevent aggregation and indicated by a 
decrease in light transmission. For the quantitative evaluation of both 
processes, the results are expressed as the maximum change in the 
transmission of light within 5 min after stimulation. 
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Fig. 1. DMS-1-P-induced platelet activation. A: Platelets were chal-
lenged with 20 uM DMS-l-P as indicated by the arrow. The shape 
change was observed turbidimetrically. The decrease in light trans-
mission of a platelet suspension monitors the change from the dis-
coid to the spheroid shape [24]. B: Platelets were stimulated with 40 
uM DMS-l-P as indicated by the arrow. The intracellular Ca2+ 
concentration was monitored using the Ca2+-sensitive fluorophore 
fura2. 
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Fig. 2. Chemical structure of sphingolipids used in this study. 1: 
Sph-l-P; 2: DMS-l-P; 3: Cer-l-P; 4: Sph; 5: DMS; 6: Cer 
2.5. Measurement of intracellular Ca2+ concentration 
Intracellular Ca2+ concentration was measured using the Ca2+-sen-
sitive fluorophore fura2 as previously described [9]. The values of the 
calcium peak increases after the addition of each agent were quanti-
fied by fluorometry. 
2.6. [sH]Sph-l-P binding assays 
The binding assays were performed by incubating intact platelets 
(1 X108 cells), which were suspended in phosphate-buffered saline, 
with 2.1 nM [3H]Sph-l-P. The reactions were initiated by the addition 
of a ligand and were incubated at 4°C for 1 h. The platelets were then 
washed three times with a solution of 1 mg/ml of bovine serum albu-
min, 150 mM NaCl, and 50 mM Tris-HCl (pH 7.5). The radioactivity 
of the platelets was counted by liquid scintillation counting. Under the 
experimental conditions, the added [3H]Sph-l-P remained intact, as 
confirmed by separation by thin layer chromatography. 
Total binding was defined as the amount of radioactivity bound to 
platelets in the absence of a competing ligand. Non-specific binding 
was defined as the amount of [3H]Sph-l-P binding that occurred in 
the presence of excess amount of (50 uM) Sph-l-P. Specific binding 
was defined as the difference between the total and the non-specific 
binding. 
3. Results and discussion 
3.1. Effects of various Sph derivatives, including DMS-l-P, on 
platelet functional responses 
Platelets show several responses that can be studied sepa-
rately in vitro but are closely linked during hemostasis in 
vivo: adhesion, shape change, aggregation, and secretion [8]. 
If platelets are in a suspension, the first response to stimula-
tion is shape change, followed by aggregation and secretion. 
Metabolic energy is required at all stages of platelet activa-
tion, and the various responses have different energy require-
ments increasing in the order: shape change < aggregation < 
granule secretion [21,22]. When human platelets were stimu-
lated with D M S - l - P , a marked shape change reaction was 
observed by the turbidimetric method (Fig. 1A). However, 
D M S - l - P did not elicit platelet aggregation or secretion of 
5-hydroxytryptamine (data not shown). D M S - l - P , which 
was only able to induce the shape change reaction, may be 
classified as a weak platelet agonist. 
It is acknowledged that intracellular Ca 2 + mobilization 
plays a central role in eliciting platelet functional responses 
[8]. Hence, we studied the effects of D M S - l - P on Ca 2 + levels 
in human platelets. As expected, D M S - l - P induced a prompt 
increase in [Ca2+]i, peaking within 20 s of addition (Fig. IB). 
The intracellular C a 2 + mobilization seems important for 
platelet activation induced by D M S - l - P , as is the case with 
Sph- l -P [9,10]. 
We next compared the effects of various sphingolipids, in-
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Table 1 
Effects of various Sph derivatives on platelet shape change, aggregation, and [Ca2+]; 
Sph derivative Shape change (%) Aggregation (%) [Ca +]i increase (nM) 
Sph 
Sph-l-P 
DMS 
DMS-l-P 
Cer (type III) 
C2-Cer 
Cer-l-P 
DL-f/areo-Dihydrosphingosine 
Lactosylceramide 
ND 
4.8 ±0.2 
ND 
4.4 ±0.5 
ND 
ND 
4.5 ±0.1 
ND 
ND 
ND 
14.7 ±3.0 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
54.7 ±8.9 
ND 
40.3 ±10.7 
ND 
ND 
NP 
ND 
ND 
Platelets were stimulated with various Sph derivatives, and shape change, aggregation, and [Ca2+]i increase were examined. The concentrations of 
Sph derivatives used were 10 |xM for shape change and [Ca2+]; increase, and 40 |j,M for aggregation. The values represent the mean ± S.D. (n = 3). 
ND, not detectable. NP, not performed. 
eluding DMS-l-P, on platelet shape change, aggregation, and 
[Ca2+]i increase under the same conditions (Fig. 2 and Table 
1). In addition to Sph-l-P, which had been found to be a 
platelet activator [9,10], both DMS-l-P (see above) and Cer-
l-P induced a marked shape change. When platelet aggrega-
tion, a more energy-requiring process than shape change 
[21,22], was examined, only Sph-l-P was capable of inducing 
the response. Sph-l-P and DMS-l-P were confirmed to induce 
intracellular Ca2+ mobilization, which is related to platelet 
activation, especially shape change [8]. Although phosphoryl-
ated sphingolipids such as Sph-l-P, DMS-l-P, and Cer-l-P 
elicited platelet functional responses, their unphosphorylated 
compounds, i.e. Sph, DMS, and Cer, did not. It should be 
noted that DMS and DMS-l-P exert contrasting effects on 
platelets; DMS inhibits protein kinase C and Sph kinase 
and hence suppresses platelet functional responses [13,14,23], 
while DMS-l-P is a platelet activator (see above). 
3.2. Inhibition by DMS-l-P of specific [sH]Sph-l-P binding to 
platelets 
As described above, phosphorylated sphingolipids specifi-
cally elicit platelet activation, and among them Sph-l-P is 
the strongest platelet activator in that it was the only one 
capable of inducing platelet aggregation, a more energy-re-
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Fig. 3. Inhibition of the [3H]Sph-l-P binding to platelets by DMS-
l-P. Platelets were incubated with [3H]Sph-l-P alone or in the addi-
tional presence of various concentrations of unlabeled Sph-l-P (o), 
DMS-l-P (□), and Sph (A) . The specific [3H]Sph-l-P binding to 
platelets is expressed as a percentage of the control (without the un-
labeled ligand). 
quiring process. We are now postulating that Sph-l-P acts 
on platelets via an interaction with a plasma membrane re-
ceptor. Platelets were found to possess two binding sites for 
Sph-l-P; the K& values were estimated to be 110 nM and 2.6 
uM, and the numbers of binding sites approximately 200/cell 
and 2400/cell, respectively [10]. Since the existence of a mono-
ester phosphate moiety seems important in the ligand-receptor 
interaction of the sphingolipids, we hypothesized that the 
mono-ester phosphate moiety of Sph-l-P is important for its 
interaction with the platelet surface receptor and that DMS-1-
P, through the moiety including mono-ester phosphate, cross-
reacts with the putative Sph-l-P receptor. Accordingly, com-
petition binding experiments of [3H]Sph-l-P were performed 
using DMS-l-P (Fig. 3). DMS-l-P reduced the binding of 
[3H]Sph-l-P to platelets almost as much as unlabeled Sph-1-
P did, while Sph was unable to compete for the [3H]Sph-l-P 
binding sites on platelets under the same conditions. Although 
DMS-l-P effectively displaces [3H]Sph-l-P binding to plate-
lets, it is unlikely that DMS-l-P fully activates the pathways 
derived from the Sph-l-P receptor. Rather, DMS-l-P may be 
a partial agonist for this receptor, which may be related to the 
facts that only Sph-l-P (but not DMS-l-P) induces platelet 
aggregation, and that Sph-l-P induces intracellular Ca2+ mo-
bilization more strongly than DMS-l-P. 
In conclusion, our data demonstrate that DMS-l-P, as well 
as Sph-l-P, activates platelets, and that these phosphorylated 
sphingolipids may bind to the same cell surface receptor. In 
view of our previous report that DMS-l-P can be formed 
from DMS in activated platelets [12], the fact that phospho-
rylation of the anti-platelet agent DMS results in a platelet 
activator may be of physiological importance. We believe that 
the functional effects of DMS-l-P in various cell systems are 
an important subject for future study. 
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